

# ASHOK SHARMA & ASSOCIATES

## CHARTERED ACCOUNTANTS

311, "DEEP SHIKHA",  
RAJENDRA PLACE,  
NEW DELHI - 110 008  
TEL: 25769764

To

The Board of Directors,  
**Medicamen Biotech Ltd.**  
10, Community Centre No-2,  
Ashok Vihar, Phase-II  
Delhi-110052

### REVIEW REPORT

We have reviewed the accompanying statement of unaudited financial results of Medicamen Biotech Limited for the period ended 30<sup>th</sup> September, 2015 except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/ Committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For ASHOK SHARMA & ASSOCIATES  
CHARTERED ACCOUNTANTS

PLACE: NEW DELHI  
DATE: 14/11/2015



# MEDICAMEN Biotech Limited




Regd. Office :  
10, Community Centre No. 2,  
Ashok Vihar, Phase-II  
Delhi-110052  
CIN No. : L74899DL1993PLC056594

Tel. : 27463506, 47589500  
Toll Free No. : 1800 3000 7889,  
1800 1029 010  
Fax : 011-27138171  
Web : www.medicamen.com

## Provisional Financial Results for the quarter ended 30th September 2015

PART I						(Rs. In Lacs)
Particulars	3 Months Ended 30/09/2015	Preceding 3 Months Ended 30/06/2015	Corresponding 3 Months Ended 30/09/2014	6 Months Ended 30/09/2015	Year Ended 31/03/2015	
	Unaudited	Unaudited	Unaudited	Unaudited	Audited	
<b>01. Income from operations</b>						
(a) Net Sales/Income from operations (Net of excise duty)	1794.21	1723.03	2730.76	3517.23	7779.38	
(b) Other Operating Income	0.00	0	0.00	0.00	0.00	
<b>(c) Total Income from Operations (Net)</b>	<b>1794.21</b>	<b>1723.03</b>	<b>2730.76</b>	<b>3517.23</b>	<b>7779.38</b>	
<b>02. Expenses</b>						
a) Cost of Material Consumed	1253.06	1084.88	1628.85	2337.94	4903.03	
b) Purchase of Goods Traded	17.85	22.51	146.81	40.36	305.37	
c) Changes in inventory of Finished Goods and Work in Progress	(99.03)	56.78	223.57	(42.25)	(33.01)	
d) Employees Benefits Expenses	165.81	162.86	154.47	328.67	643.39	
e) Depreciation and Amortisation Expenses	47.46	46.55	53.15	94.01	209.67	
f) Other expenses	334.01	322.85	408.19	656.86	1567.55	
<b>TOTAL EXPENSES</b>	<b>1719.16</b>	<b>1696.43</b>	<b>2615.04</b>	<b>3415.59</b>	<b>7596.00</b>	
<b>03. Profit/(Loss) from Operations before other Income, Finance Cost and Exceptional Items (1-2)</b>	<b>75.04</b>	<b>26.60</b>	<b>115.73</b>	<b>101.64</b>	<b>183.38</b>	
04. Other Income	32.02	24.51	16.38	56.53	110.04	
<b>05. Profit/(Loss) from ordinary activities before Finance Cost and Exceptional Items (3+4)</b>	<b>107.06</b>	<b>51.11</b>	<b>132.11</b>	<b>158.17</b>	<b>293.42</b>	
06. Finance Cost	75.01	77.19	70.95	152.21	281.33	
<b>07. Profit/(Loss) from Ordinary Activities after Finance Cost but before Exceptional Items (5-6)</b>	<b>32.05</b>	<b>(26.09)</b>	<b>61.15</b>	<b>5.96</b>	<b>12.09</b>	
08. Exceptional Items	0.00	0.00	0.00	0.00	0.00	
<b>09. Profit /Loss from Ordinary Activities before tax (7+8)</b>	<b>32.05</b>	<b>(26.09)</b>	<b>61.15</b>	<b>5.96</b>	<b>12.09</b>	
10. Tax Expenses						
Current Year	1.14	0.00	11.65	1.14	2.30	
Tax Related to Earlier Year	0.00	0.00	0.00	0.00	0.00	
Deferred Tax Liability	(4.18)	(3.30)	(0.54)	(7.48)	(34.27)	
<b>11. Net Profit /Loss from Ordinary Activities After Tax (9-10)</b>	<b>35.10</b>	<b>(22.79)</b>	<b>50.04</b>	<b>12.31</b>	<b>44.06</b>	
12. Extraordinary Items (Net of Tax expenses)	-	-	-	-	-	
<b>13. Net Profit/Loss for the period (11-12)</b>	<b>35.10</b>	<b>(22.79)</b>	<b>50.04</b>	<b>12.31</b>	<b>44.06</b>	
14. Paid-up equity share capital (Rs.10/- per share)	999.36	999.36	891.36	999.36	951.13	
15. Reserve excluding revaluation reserves					738.61	
<b>16. Earning Per Share before &amp; after extraordinary items (Rs.) (not annualised)</b>						
Basic	0.39	(0.26)	0.56	0.12	0.49	
Diluted	0.39	(0.26)	0.56	0.12	0.49	



PART II					
Select Information for the Quarter and Year ended 30/09/2015					
Particulars	3 Months	Preceding	Corresponding 3	6 Months Ended	Year Ended
	Ended 30/09/2015	3 Months Ended 30/06/2015	Months Ended 30/09/2014	30/09/2015	31/03/2015
<b>A PARTICULARS OF SHAREHOLDING</b>					
1 Public Shareholding					
- No. of Shares	52,76,218	52,76,218	51,43,518	52,76,218	5276218
- Percentage of Shareholding	52.80	52.80	57.70	52.80	55.47
2 Promoters and Promoter Group Shareholding					
a) Pledged /Encumbered					
- Number of Shares	11,61,200	11,61,200	18,61,200	11,61,200	1161200
- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	24.62	24.62	49.37	24.62	27.42
- Percentage of Shares (as a % of the total share capital of the company)	11.62	11.62	20.88	11.62	12.21
b) Non-Encumbered					
- Number of Shares	35,56,188	35,56,188	19,08,888	35,56,188	3073888
- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	75.38	75.38	50.63	75.38	72.58
- Percentage of Shares (as a % of the total share capital of the company)	35.58	35.58	21.41	35.58	32.32

Particulars	3 Months ended 30/09/2015
<b>B INVESTOR COMPLAINTS</b>	
Pending at the beginning of the quarter	NIL
Received during the quarter	NIL
Disposed of during the quarter	NIL
Remaining unresolved at the end of the quarter	NIL

Particulars	As at	As at
	30/09/2015 Unaudited	31/03/2015 Audited
<b>EQUITY AND LIABILITIES</b>		
<b>Shareholders' Fund</b>		
(a) Share Capital	999.36	951.13
(b) Reserves and Surplus	755.74	738.61
(c) Money Received against Share Warrants	0.00	28.72
	1755.10	1,718.46
<b>Non-current Liabilities</b>		
(a) Long-term borrowings	419.54	458.98
(b) Deferred Tax liabilities (Net)	57.97	65.46
(c) Long-term Provisions	154.83	149.09
	632.34	673.52
<b>Current Liabilities</b>		
(a) Short term borrowings	1515.83	1,556.00
(b) Trade payables	2542.10	2,652.47
(c) Other current liabilities	300.32	253.95
(d) Short term provisions	10.52	11.86
	4368.77	4,474.28
<b>TOTAL- EQUITY AND LIABILITIES</b>	<b>6756.21</b>	<b>6,866.26</b>



**ASSETS****Non-current assets****(a) Fixed assets**

(i) Tangible assets

1926.50 1,979.66

(ii) Intangible assets

3.52 3.97

(iii) Capital work-in-progress

0.00 0.00

**(b) Long-term loans and advances**

32.02 31.79

1962.04 2,015.42

**Current assets****(a) Current investments**

2.00 2.00

**(b) Inventories**

1425.65 1,346.36

**(c) Trade receivables**

2515.32 2,651.43

**(d) Cash and Bank Balances**

266.23 229.40

**(e) Short-term loans and advances**

390.90 450.13

**(f) Other current assets**

194.07 171.53

4794.18 4,850.85

**TOTAL- ASSETS**

6756.21 6,866.26

**NOTES :**

1. The above results after being reviewed by the Audit Committee were taken on record by the Board at its Meeting held on 14th November, 2015
2. Limited Review as required under Clause 41 of Listing Agreement has been carried out by the statutory auditors.
3. The figures are regrouped in previous year also, wherever considered necessary.
4. The company operates in single segment, viz. Pharmaceutical Formulations.
5. On September 16, 2015 Acquirer along with Persons Acting in Concern (PAC) has given Takeover Open Offer to acquire 25,98,388 equity shares representing 26% of Paid up Capital from the Public. The Offer is in process.

Place ; Delhi

Dated : 14.11.2015

For & on behalf of Board of  
Medicamen Biotech Limited

(B.K. Gupta)  
Managing Director